Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ORIC Oric Pharmaceuticals Inc.

Trading 02-27 14:04:49 EST

13.46

-0.04

-0.30%

High13.73	Low12.85	Vol326.47K
Open12.88	D1 Closing13.50	Amplitude6.51%
Mkt Cap1.35B	Tradable Cap816.47M	Total Shares100.36M
T/O4.38M	T/O Rate0.54%	Tradable Shares60.66M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ORIC","market":"US","secType":"STK","nameCN":"Oric Pharmaceuticals Inc.","latestPrice":13.46,"timestamp":1772219088065,"preClose":13.5,"halted":0,"volume":326468,"delay":0,"changeRate":-0.0029629629629629,"floatShares":60659100,"shares":100358242,"eps":-1.47,"marketStatus":"Trading","change":-0.04,"latestTime":"02-27 14:04:49 EST","open":12.88,"high":13.73,"low":12.851,"amount":4380217.89132,"amplitude":0.065111,"askPrice":13.47,"askSize":12,"bidPrice":13.46,"bidSize":228,"shortable":3,"etf":0,"ttmEps":-1.47,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772226000000},"marketStatusCode":2,"adr":0,"listingDate":1587700800000,"exchange":"NASDAQ","adjPreClose":13.5,"preHourTrading":{"tag":"盘前","latestPrice":12.92,"preClose":13.5,"latestTime":"09:29 EST","volume":13297,"amount":175752.100225,"timestamp":1772202599945,"change":-0.58,"changeRate":-0.042963,"amplitude":0.133333},"postHourTrading":{"tag":"盘后","latestPrice":13.5,"preClose":13.5,"latestTime":"18:39 EST","volume":17255,"amount":232939.67,"timestamp":1772149180848,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.174555,"impliedVol":0.3548,"impliedVolPercentile":0.0637},"requestUrl":"/m/hq/s/ORIC/tweets","defaultTab":"tweets","newsList":[{"id":"2614710260","title":"Oric Pharmaceuticals CFO Dominic Piscitelli Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2614710260","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614710260?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:54","pubTimestamp":1772142854,"startTime":"0","endTime":"0","summary":"Dominic Piscitelli, Chief Financial Officer of Oric Pharmaceuticals Inc, reported a disposal of common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 26, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL2pKsnw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oric Pharmaceuticals CFO Dominic Piscitelli Disposes of Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"gpt_icon":0},{"id":"2614703962","title":"A Look At ORIC Pharmaceuticals (ORIC) Valuation After Phase 1b Results And Extended Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2614703962","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614703962?lang=en_us&edition=fundamental","pubTime":"2026-02-25 23:35","pubTimestamp":1772033712,"startTime":"0","endTime":"0","summary":"Why ORIC Pharmaceuticals stock is back on investors’ radar\nORIC Pharmaceuticals (ORIC) has drawn fresh attention after reporting Phase 1b data for its lead cancer drugs and securing new funding that management expects will cover operations into the second half of 2028.\nSee our latest analysis for ORIC Pharmaceuticals.\nThe recent Phase 1b readouts, extended cash runway into late 2028 and new equity programs have all landed alongside a strong 64.26% year to date share price return. The 3 year...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/a-look-at-oric-pharmaceuticals-oric-valuation-after-phase-1b","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/a-look-at-oric-pharmaceuticals-oric-valuation-after-phase-1b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ORIC","BK4139"],"gpt_icon":0},{"id":"2614374552","title":"Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2614374552","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614374552?lang=en_us&edition=fundamental","pubTime":"2026-02-24 23:55","pubTimestamp":1771948536,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Robert Burns raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $25 from $23 and keeps a Buy rating on the sh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oric-pharmaceuticals-price-target-raised-to-25-from-23-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oric-pharmaceuticals-price-target-raised-to-25-from-23-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC","BK4139"],"gpt_icon":0},{"id":"2613743094","title":"Oric Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $25 From $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2613743094","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613743094?lang=en_us&edition=fundamental","pubTime":"2026-02-24 23:51","pubTimestamp":1771948303,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nAZN4SI14U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORIC"],"gpt_icon":0},{"id":"2613352717","title":"Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2613352717","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613352717?lang=en_us&edition=fundamental","pubTime":"2026-02-24 22:01","pubTimestamp":1771941660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ORIC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2026 09:01 ET (14:01 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"gpt_icon":0},{"id":"2613771467","title":"Oppenheimer Sticks to Their Buy Rating for Oric Pharmaceuticals (ORIC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613771467","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613771467?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:16","pubTimestamp":1771938973,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Oric Pharmaceuticals today and set a price target of $15.00. According to TipRanks, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC","OPY"],"gpt_icon":0},{"id":"2613122755","title":"Oric Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2613122755","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613122755?lang=en_us&edition=fundamental","pubTime":"2026-02-24 07:15","pubTimestamp":1771888506,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings SummaryOric Pharmaceuticals Inc ORIC.OQ reported a quarterly adjusted loss of 30 cents per share for the quarter e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL8N3ZJ2HS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"gpt_icon":0},{"id":"2613675550","title":"Oric Pharmaceuticals Launches New 2026 ATM Share Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2613675550","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613675550?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:53","pubTimestamp":1771887228,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals ( ($ORIC) ) just unveiled an update. On May 6, 2021, ORIC Pharmaceuticals, Inc. entered into an Open Market Sale Agreement wit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oric-pharmaceuticals-launches-new-2026-atm-share-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oric-pharmaceuticals-launches-new-2026-atm-share-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ORIC"],"gpt_icon":0},{"id":"2613536047","title":"Oric Pharmaceuticals - May Offer & Sell Shares of Common Stock of up to $200 Mln From Time to Time Through Jefferies - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2613536047","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613536047?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:26","pubTimestamp":1771885560,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nFWN3ZJ120:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORIC","BK4139"],"gpt_icon":0},{"id":"2613475380","title":"ORIC Pharmaceuticals Q4 EPS $(0.30) Beats $(0.37) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2613475380","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613475380?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:17","pubTimestamp":1771885053,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.37) by 18.7 percent. This is a 41.18 percent increase over losses of $(0.51) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50802492/oric-pharmaceuticals-q4-eps-0-30-beats-0-37-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ORIC Pharmaceuticals Q4 EPS $(0.30) Beats $(0.37) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC"],"gpt_icon":0},{"id":"2613308057","title":"ORIC Pharmaceuticals Q4 loss narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2613308057","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613308057?lang=en_us&edition=fundamental","pubTime":"2026-02-24 05:18","pubTimestamp":1771881483,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals Q4 loss narrowsOverviewOncology firm's Q4 net loss narrowed to $30.5 mln from $36.3 mln last yearCompany raised $264 mln, extending cash runway into 2H 2028Significant clinical ad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL1N3ZJ10Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"gpt_icon":0},{"id":"2613379747","title":"ORIC Q4 net loss USD 30.51 million, R&D expenses USD 25.86 million -19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613379747","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613379747?lang=en_us&edition=fundamental","pubTime":"2026-02-24 05:05","pubTimestamp":1771880754,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via GlobeNewswire  on February 23, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL971bBd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BKPKM429.USD","ORIC","SG9999014021.USD","BK4585","LU2210149790.SGD","LU2095319765.USD","BK4139","BK4588","LU2210150020.SGD","SG9999014005.SGD","BK4112","SG9999014013.SGD","SG9999014039.USD","LU0314104364.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ"],"gpt_icon":0},{"id":"2613737982","title":"BRIEF-ORIC Pharmaceuticals Q4 Net Income USD -30.505 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2613737982","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613737982?lang=en_us&edition=fundamental","pubTime":"2026-02-24 05:05","pubTimestamp":1771880747,"startTime":"0","endTime":"0","summary":"BRIEF-ORIC Pharmaceuticals Q4 Net Income USD -30.505 Million\n\n\nFeb 23 (Reuters) - ORIC Pharmaceuticals Q4 operating expenses USD 34.551 million.\n\nQ4 income from operations USD -34.551 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nPLX93AD55:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"gpt_icon":0},{"id":"2613737626","title":"Oric Pharmaceuticals Q4 Operating Expenses USD 34.551 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2613737626","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613737626?lang=en_us&edition=fundamental","pubTime":"2026-02-24 05:05","pubTimestamp":1771880702,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nPLX93AD55:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORIC","BK4139"],"gpt_icon":0},{"id":"2613730491","title":"ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2613730491","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613730491?lang=en_us&edition=fundamental","pubTime":"2026-02-24 05:05","pubTimestamp":1771880700,"startTime":"0","endTime":"0","summary":"Reported rinzimetostat (formerly ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/23/3243033/0/en/ORIC-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Operational-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"gpt_icon":0},{"id":"2609114055","title":"Oric Pharmaceuticals Grants Stock Options and Restricted Stock Units to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2609114055","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609114055?lang=en_us&edition=fundamental","pubTime":"2026-02-07 05:30","pubTimestamp":1770413408,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals Inc. has granted a total of 173,800 non-qualified stock options and 28,700 restricted stock units to three new non-executive employees who joined the company in January 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via GlobeNewswire  on February 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL6Qp0ss:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BGHQF748.EUR","SG9999014013.SGD","BK4588","BK4585","BK4139","BK4112","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","SG9999014005.SGD","LU2210149790.SGD","NDAQ","LU2210150020.SGD","IE00BKPKM429.USD","LU0314104364.USD","ORIC","LU2095319765.USD","SG9999014021.USD"],"gpt_icon":0},{"id":"2609511472","title":"Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2609511472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609511472?lang=en_us&edition=fundamental","pubTime":"2026-02-07 05:30","pubTimestamp":1770413400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nTUA10HG2T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORIC"],"gpt_icon":0},{"id":"2609781511","title":"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2609781511","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609781511?lang=en_us&edition=fundamental","pubTime":"2026-02-07 05:30","pubTimestamp":1770413400,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb.  06, 2026  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/06/3234085/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"gpt_icon":0},{"id":"2609581692","title":"ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2609581692","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609581692?lang=en_us&edition=fundamental","pubTime":"2026-02-06 05:01","pubTimestamp":1770325260,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb.  05, 2026  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that addres","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/05/3233410/0/en/ORIC-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"gpt_icon":0},{"id":"2605286851","title":"Oric Pharmaceuticals Director Richard A. Heyman Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605286851","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605286851?lang=en_us&edition=fundamental","pubTime":"2026-01-21 08:19","pubTimestamp":1768954795,"startTime":"0","endTime":"0","summary":"Richard A. Heyman, Director at Oric Pharmaceuticals Inc, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL3kXLCh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oric Pharmaceuticals Director Richard A. Heyman Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oricpharma.com","stockEarnings":[{"period":"1week","weight":0.1915},{"period":"1month","weight":0.1148},{"period":"3month","weight":0.1364},{"period":"6month","weight":0.3196},{"period":"1year","weight":0.6265},{"period":"ytd","weight":0.6504}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":-0.0089},{"period":"3month","weight":0.0086},{"period":"6month","weight":0.0686},{"period":"1year","weight":0.1594},{"period":"ytd","weight":0.0108}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.039993},{"month":2,"riseRate":0.5,"avgChangeRate":-0.013663},{"month":3,"riseRate":0.4,"avgChangeRate":-0.098966},{"month":4,"riseRate":0.2,"avgChangeRate":-0.164176},{"month":5,"riseRate":0.666667,"avgChangeRate":0.07899},{"month":6,"riseRate":0.666667,"avgChangeRate":0.141043},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.000511},{"month":8,"riseRate":0.666667,"avgChangeRate":0.090659},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.048915},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.0811},{"month":11,"riseRate":0.666667,"avgChangeRate":0.167402},{"month":12,"riseRate":0.5,"avgChangeRate":0.06155}],"exchange":"NASDAQ","name":"Oric Pharmaceuticals Inc.","nameEN":"Oric Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oric Pharmaceuticals Inc.(ORIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oric Pharmaceuticals Inc.,ORIC,Oric Pharmaceuticals Inc.股票,Oric Pharmaceuticals Inc.股票老虎,Oric Pharmaceuticals Inc.股票老虎国际,Oric Pharmaceuticals Inc.行情,Oric Pharmaceuticals Inc.股票行情,Oric Pharmaceuticals Inc.股价,Oric Pharmaceuticals Inc.股市,Oric Pharmaceuticals Inc.股票价格,Oric Pharmaceuticals Inc.股票交易,Oric Pharmaceuticals Inc.股票购买,Oric Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oric Pharmaceuticals Inc.(ORIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction